Back to Blog

    ZYN Clears the FDA’s Highest Bar, as Pouches Overtake US Oral Tobacco

    August 24, 2026
    ZYN Clears the FDA’s Highest Bar, as Pouches Overtake US Oral Tobacco

    At the end of June the US Food and Drug Administration (FDA) authorized Swedish Match, now part of Philip Morris International (PMI), to sell its ZYN nicotine pouch products carrying an explicit health claim: “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” This is a modified risk tobacco product (MRTP) order, and close to the most the FDA can say about a reduced-risk nicotine product short of approving a medicine.

    The signals that this MRTP authorization sends

    New nicotine products are supposed to require marketing authorization, granted only when a product is deemed to be “appropriate for the protection of public health”, simply to be sold in the US. That’s already a high hurdle, but an MRTP order goes further: after reviewing the science, the FDA lets a named product carry a specific health claim it judges both supported and unlikely to mislead. These orders are scarce, and, including ZYN, only a handful of product families have earned one: among those are Philip Morris’s IQOS and General snus, and Altria’s Copenhagen snuff.

    In our view the consequence is less what it does for one brand than the signal it sends. For consumers, a reduced-risk claim on the can or the advert is science-based information at the point of choice, aimed at the adults who smoke and might otherwise not know that a pouch is safer than a cigarette. For regulators elsewhere in the world the fact that a cautious US agency has now granted a disease-risk claim is also an important marker, in the context of the science behind tobacco harm reduction (THR) often still being contested.

    There may well be implications for the wider category too. On August 4 the FDA cleared four on! pouches, from Altria, for sale. That was a plain marketing authorization rather than an MRTP, so on! cannot make ZYN’s claim. But a consumer who hears that the FDA has allowed a lower-risk claim for the best-selling pouch may reasonably take a similar view of pouches in general; the ZYN order may cast a halo over the wider category.

    There is a further signal in what the FDA was willing to clear. The authorized ZYN range runs well beyond mint and menthol, taking in citrus, coffee and cinnamon, and FDA is also allowing on! to sell pouches with berry flavor. That matters, because flavor is part of what makes a pouch an acceptable substitute for a cigarette. The agency has so far been markedly more reluctant to accept the same for e-cigarettes: of the 45 products it has authorized, all but two are tobacco- or menthol-flavored, and those two were only authorized in May 2026. It’s good that the FDA appears to be recognizing that flavor has a role in getting people to switch.

    A category growing fast

    The order arrives as nicotine pouches overtake the rest of the US oral tobacco market. By the first half of 2026 they made up nearly 60% of the category, up nearly nine percentage points in a year and from a standing start about a decade ago. The competition behind that growth is broadening: as well as PMI’s ZYN and Altria’s on!, BAT’s Velo has also been growing well and Imperial Brands, which sells Zone pouches, announced the purchase of another US smokeless business, Black Buffalo, in May 2026. This type of significant investment in a category is generally good for growth, as marketing, distribution and shelf space all expand behind the format.

    Regulation edging toward the science

    Not everybody likes this decision. The American Heart Association professed itself “deeply concerned” at the FDA’s ZYN decision, arguing that flavored products would appeal to youth, and published a very similar press release related to the on! decision a few weeks later. Those kinds of concerns are embedded in the FDA process: companies have to monitor youth use of their products, and the agency has the power to remove both MRTP designation and marketing authorizations if it finds that youth consumption of the relevant products has become a significant concern.

    The real statistics on youth use of tobacco and nicotine products look encouraging to us. The National Youth Tobacco Survey is the annual, nationally representative survey of US students run by the FDA (with the Centers for Disease Control and Prevention); it is the main yardstick for youth tobacco and nicotine use in the country. Its 2025 round, published this June, put past 30-day nicotine-pouch use at 2.3% of high school students, down very slightly on the previous year. That compares to 7.1% for e-cigarettes, and 3.2% for any combustible tobacco product. In 2016 11.3% of high-school students had used e-cigarettes in the past 30 days, and 13.8% had used a combustible tobacco product. No child ought to be using a tobacco or nicotine product, but the statistics show what seems to be an overall reassuring picture: youth use of all tobacco and nicotine products seems to be trending downwards, and most steeply in the most dangerous products: cigarettes.

    A cautious agency putting its name to a disease-risk claim for a mainstream consumer product is exactly the risk-proportionate regulation on which our case for engaging with the transition of the tobacco and nicotine industry, rather than shunning it, depends. Our view on the long-term value in these businesses turns on how successfully they can move those who smoke and use nicotine onto lower-risk products. These FDA decisions move US regulation a step closer to the science, and a regulator willing to allow accurate relative-risk messaging on packs should help our transition thesis along.

    An investor should consider the investment objectives, risks, and charges and expenses of the fund carefully before investing. A prospectus which contains this and other information about the fund may be obtained by calling 1-800-617-0004, or by clicking here. The prospectus should be read carefully before investing.

    Investing involves risk. Principal loss is possible. The Fund is a recently organized entity, giving prospective investors a limited track record on which to base their investment decision. The Fund’s investments will be concentrated in the securities of issuers in the tobacco, or nicotine-related group of industries. The tobacco industry is subject to significant risks and uncertainties that could materially and adversely affect the financial condition and cash flows, of companies operating in it. Investing in foreign securities typically involves more risks than investing in U.S. securities, and includes risks associated with: (i) internal and external political and economic developments – e.g., the political, economic and social policies and structures of some foreign countries may be less stable and more volatile than those in the U.S. or some foreign countries may be subject to trading restrictions or economic sanctions; (ii) trading practices – e.g., government supervision and regulation of foreign securities and currency markets, trading systems and brokers may be less than in the U.S.; (iii) availability of information – e.g., foreign issuers may not be subject to the same disclosure, accounting and financial reporting standards and practices as U.S. issuers; (iv) limited markets – e.g., the securities of certain foreign issuers may be less liquid (harder to sell) and more volatile; and (v) currency exchange rate fluctuations and policies. Investment in emerging market securities involves greater risk than that associated with investment in securities of issuers in developed foreign countries.

    Derivatives may pose risks in addition to and greater than those associated with investing directly in securities, currencies or other investments, including risks relating to leverage, imperfect correlations with underlying investments or the Fund’s other portfolio holdings, high price volatility, lack of availability, counterparty credit, liquidity, valuation and legal restrictions. A total return swap is a contract in which one party agrees to make periodic payments to another party based on the change in market value of the assets underlying the contract, which may include a specified security, basket of securities, or securities indices during the specified period, in return for periodic payments based on a fixed or variable interest rate or the total return from other underlying assets. The Fund is a non-diversified, investment company under the 1940 Act. Because the Fund is non-diversified, it will invest a greater percentage of its assets in the securities of a limited number of issuers. Investing in medium and small capitalization companies may involve special risks because those companies may have narrower product lines, more limited financial resources, fewer experienced managers, dependence on a few key employees, and a more limited trading market for their stocks, as compared with larger companies. The securities of micro-cap companies may be more volatile in price, have wider spreads between their bid and ask prices, and have significantly lower trading volumes than the securities of larger capitalization companies.

    ETFs are subject to risks that the market price of an ETF's shares may trade at a premium or discount to its net asset value, an active secondary trading market may not develop or be maintained, or trading may be halted by the exchange in which they trade, which may impact an ETF's ability to sell its shares. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. Brokerage commissions will reduce returns.

    The Hexis Nicotine Transition Score (HNTS) is a proprietary framework reflecting the manager’s subjective assessments; independent review by ACA Ethos is not an endorsement of the Fund.

    ETF holdings are subject to change and are not recommendations to buy or sell any security. For current holdings, please click here: Hexis Capital Management | <NICO>

    The Hexis Active Nicotine Engagement ETF is distributed by Quasar Distributors, LLC

    Definitions used on these pages:

    R&D: Research and development spend – investment in developing new products, technologies, or capabilities.

    M&A: Mergers and acquisitions spend – spending on acquiring or merging with other companies to expand scale, capabilities, or market access.

    Capex: Capital expenditure – investment in long-term physical or intangible assets such as facilities, equipment, or infrastructure.

    Discounted Cash Flow (DCF) model – a valuation method that estimates a company’s value by discounting its expected future cash flows back to today.

    Terminal value – the estimated value of a business beyond the explicit forecast period in a DCF model.

    Terminal growth rate – the assumed long-term, steady growth rate used to calculate terminal value.

    EV: Enterprise Value – a measure of a company’s total value, calculated as market capitalisation plus net debt.

    EBITDA: Earnings before interest, taxes, depreciation and amortisation.